Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Neurocrine Biosciences (NBIX) Equity Income (2019 - 2025)

Neurocrine Biosciences (NBIX) has disclosed Equity Income for 6 consecutive years, with $2.7 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Equity Income rose 242.11% year-over-year to $2.7 million, compared with a TTM value of -$4.0 million through Dec 2025, up 89.22%, and an annual FY2025 reading of -$4.0 million, up 89.22% over the prior year.
  • Equity Income was $2.7 million for Q4 2025 at Neurocrine Biosciences, down from $30.6 million in the prior quarter.
  • Across five years, Equity Income topped out at $30.6 million in Q3 2025 and bottomed at -$40.1 million in Q3 2023.
  • Average Equity Income over 4 years is -$4.4 million, with a median of -$1.9 million recorded in 2024.
  • Peak annual rise in Equity Income hit 281.07% in 2025, while the deepest fall reached 2012.5% in 2025.
  • Year by year, Equity Income stood at -$8.2 million in 2021, then soared by 453.66% to $29.0 million in 2023, then crashed by 106.55% to -$1.9 million in 2024, then surged by 242.11% to $2.7 million in 2025.
  • Business Quant data shows Equity Income for NBIX at $2.7 million in Q4 2025, $30.6 million in Q3 2025, and -$6.7 million in Q2 2025.